Next Article in Journal
The Lean Six Sigma Define, Measure, Analyze, Implement, Control (LSS DMAIC) Framework: An Innovative Strategy for Quality Improvement of Pharmacist Vaccine Recommendations in Community Pharmacy
Previous Article in Journal
Development of a Campus-Wide Community Service Initiative during a Pandemic
Review

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review

1
Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA
2
Center for Pharmacy Innovation and Outcomes, Forty Fort, PA 18704, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Jon Schommer and Jack E. Fincham
Pharmacy 2022, 10(3), 48; https://doi.org/10.3390/pharmacy10030048
Received: 10 March 2022 / Revised: 15 April 2022 / Accepted: 16 April 2022 / Published: 19 April 2022
(This article belongs to the Special Issue Pharmacy Reviews in 2022)
The opioid epidemic is an ongoing public health crisis, and the United States health system is overwhelmed with increasing numbers of opioid-related overdoses. Methocinnamox (MCAM) is a novel mu opioid receptor antagonist with an extended duration of action. MCAM has potential to reduce the burden of the opioid epidemic by being used as an overdose rescue treatment and a long-term treatment for opioid use disorder (OUD). The currently available treatments for OUD include naloxone, naltrexone, and methadone. These treatments have certain limitations, which include short duration of action, patient non-compliance, and diversion. A narrative review was conducted using PubMed and Google Scholar databases covering the history of the opioid epidemic, pain receptors, current OUD treatments and the novel drug MCAM. MCAM could potentially be used as both a rescue and long-term treatment for opioid misuse. This is due to its pseudo-irreversible antagonism of the mu opioid receptor, abnormally long duration of action of nearly two weeks, and the possibility of using kappa or delta opioid receptor agonists for pain management during OUD treatment. MCAM’s novel pharmacokinetic and pharmacodynamic properties open a new avenue for treating opioid misuse. View Full-Text
Keywords: methocinnamox; opioid use disorder; naloxone; naltrexone; methadone; buprenorphine; overdose; treatment; receptors; addiction methocinnamox; opioid use disorder; naloxone; naltrexone; methadone; buprenorphine; overdose; treatment; receptors; addiction
Show Figures

Graphical abstract

MDPI and ACS Style

Jordan, C.G.; Kennalley, A.L.; Roberts, A.L.; Nemes, K.M.; Dolma, T.; Piper, B.J. The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. Pharmacy 2022, 10, 48. https://doi.org/10.3390/pharmacy10030048

AMA Style

Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ. The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. Pharmacy. 2022; 10(3):48. https://doi.org/10.3390/pharmacy10030048

Chicago/Turabian Style

Jordan, Colleen G., Amy L. Kennalley, Alivia L. Roberts, Kaitlyn M. Nemes, Tenzing Dolma, and Brian J. Piper. 2022. "The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review" Pharmacy 10, no. 3: 48. https://doi.org/10.3390/pharmacy10030048

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop